FDA Finds No Increased Risk of Femur Fractures in Women Taking Fosamax
The FDA has reported on its ongoing safety review of oral bisphophonates and atypical subtrochanteric femur fractures. "Recent news reports have raised the question about whether there is an increased risk of this type of fracture in patients with osteoporosis using these [Fosamax, Actonel, Boniva, Reclast] medications" "All available case reports and clinical trial data were requested. FDA's review of these data did not show an increase in this risk in women using these medications."
